Ignite Creation Date:
2025-12-24 @ 12:15 PM
Ignite Modification Date:
2026-01-04 @ 12:48 PM
Study NCT ID:
NCT02627261
Status:
COMPLETED
Last Update Posted:
2022-09-06
First Post:
2015-12-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multiple Myeloma Minimal Residual Disease
Sponsor:
Hospices Civils de Lyon
Organization:
Study Overview
Official Title:
Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MMRD
Brief Summary:
Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: